V Square Quantitative Management LLC Sells 2,351 Shares of Stryker Corporation $SYK

V Square Quantitative Management LLC lowered its holdings in shares of Stryker Corporation (NYSE:SYK) by 40.4% in the 2nd quarter, Holdings Channel.com reports. The firm owned 3,465 shares of the medical technology company’s stock after selling 2,351 shares during the quarter. V Square Quantitative Management LLC’s holdings in Stryker were worth $1,371,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the business. Norris Perne & French LLP MI lifted its position in Stryker by 378.4% during the second quarter. Norris Perne & French LLP MI now owns 17,535 shares of the medical technology company’s stock valued at $6,937,000 after purchasing an additional 13,870 shares during the last quarter. Clean Yield Group lifted its holdings in shares of Stryker by 212.2% in the 2nd quarter. Clean Yield Group now owns 14,361 shares of the medical technology company’s stock worth $5,682,000 after acquiring an additional 9,761 shares during the last quarter. Investment Advisory Services Inc. TX ADV lifted its holdings in shares of Stryker by 5.4% in the 2nd quarter. Investment Advisory Services Inc. TX ADV now owns 9,924 shares of the medical technology company’s stock worth $3,926,000 after acquiring an additional 505 shares during the last quarter. Moody Lynn & Lieberson LLC lifted its holdings in shares of Stryker by 1.0% in the 2nd quarter. Moody Lynn & Lieberson LLC now owns 87,798 shares of the medical technology company’s stock worth $34,736,000 after acquiring an additional 861 shares during the last quarter. Finally, GraniteShares Advisors LLC bought a new stake in shares of Stryker in the 2nd quarter worth about $1,281,000. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.1%

SYK stock opened at $368.83 on Monday. The company has a market capitalization of $141.01 billion, a PE ratio of 48.85, a P/E/G ratio of 2.66 and a beta of 0.93. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19. The firm’s 50-day moving average is $385.71 and its 200 day moving average is $379.18. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, topping the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm’s revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the firm posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker’s dividend payout ratio (DPR) is 44.50%.

Analysts Set New Price Targets

Several research firms have recently issued reports on SYK. Wells Fargo & Company raised their target price on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. BTIG Research restated a “buy” rating on shares of Stryker in a report on Monday, July 14th. Truist Financial set a $415.00 target price on shares of Stryker and gave the stock a “hold” rating in a report on Monday, August 4th. Evercore ISI raised their target price on shares of Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a report on Tuesday, July 8th. Finally, Rothschild & Co Redburn initiated coverage on shares of Stryker in a report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price for the company. Fourteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $430.33.

Insider Transactions at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.20% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.